piracetam has been researched along with Anxiety Disorders in 7 studies
Piracetam: A compound suggested to be both a nootropic and a neuroprotective agent.
Anxiety Disorders: Persistent and disabling ANXIETY.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This report reviews behavioral adverse events occurring among adults receiving levetiracetam (LEV) or placebo who participated in short-term, placebo-controlled studies in epilepsy (1023), cognitive disorders (719), or anxiety disorders (1510) and epilepsy patients (1393) observed in long-term trials." | 8.82 | A systematic review of the behavioral effects of levetiracetam in adults with epilepsy, cognitive disorders, or an anxiety disorder during clinical trials. ( Cramer, JA; De Rue, K; Devinsky, O; Edrich, P; Trimble, MR, 2003) |
| "Forty patients with DSM-IV anxiety disorders, who were deemed partial responders or nonresponders to anxiolytic therapy, received adjunctive levetiracetam in a naturalistic fashion during the time period from January 2004 through December 2004." | 7.74 | Levetiracetam as adjunctive therapy for refractory anxiety disorders. ( Kinrys, G; Nery, F; Pollack, MH; Reese, H; Worthington, JJ; Wygant, L, 2007) |
| "This study suggests that levetiracetam deserves further study in the treatment of alcohol dependence and co-occurring anxiety disorders." | 5.13 | Levetiracetam for the treatment of co-occurring alcohol dependence and anxiety: case series and review. ( Levin, FR; Mariani, JJ, 2008) |
| "Abnormalities in brain gamma-aminobutyric acid (GABA) and glutamate may be relevant to the underlying pathophysiology of anxiety disorders including social anxiety disorder (SAD)." | 5.13 | High-field MRS study of GABA, glutamate and glutamine in social anxiety disorder: response to treatment with levetiracetam. ( Jensen, JE; Kaufman, RE; Pollack, MH; Renshaw, PF; Simon, NM, 2008) |
| "This report reviews behavioral adverse events occurring among adults receiving levetiracetam (LEV) or placebo who participated in short-term, placebo-controlled studies in epilepsy (1023), cognitive disorders (719), or anxiety disorders (1510) and epilepsy patients (1393) observed in long-term trials." | 4.82 | A systematic review of the behavioral effects of levetiracetam in adults with epilepsy, cognitive disorders, or an anxiety disorder during clinical trials. ( Cramer, JA; De Rue, K; Devinsky, O; Edrich, P; Trimble, MR, 2003) |
| "Forty patients with DSM-IV anxiety disorders, who were deemed partial responders or nonresponders to anxiolytic therapy, received adjunctive levetiracetam in a naturalistic fashion during the time period from January 2004 through December 2004." | 3.74 | Levetiracetam as adjunctive therapy for refractory anxiety disorders. ( Kinrys, G; Nery, F; Pollack, MH; Reese, H; Worthington, JJ; Wygant, L, 2007) |
| "The purpose of this analysis was to compare treatment-emergent adverse events (TEAE) related to use of levetiracetam (LEV) reported by young and elderly patients with anxiety and cognitive disorders, and young epilepsy patients." | 3.72 | Tolerability of levetiracetam in elderly patients with CNS disorders. ( Cramer, JA; Edrich, P; Krämer, G; Leppik, IE; Rue, KD, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (85.71) | 29.6817 |
| 2010's | 1 (14.29) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Taneja, R | 1 |
| Hunter, K | 1 |
| Burakgazi-Dalkilic, E | 1 |
| Carran, M | 1 |
| Mariani, JJ | 1 |
| Levin, FR | 1 |
| Cramer, JA | 2 |
| De Rue, K | 1 |
| Devinsky, O | 1 |
| Edrich, P | 2 |
| Trimble, MR | 1 |
| Leppik, IE | 1 |
| Rue, KD | 1 |
| Krämer, G | 1 |
| Kinrys, G | 1 |
| Worthington, JJ | 1 |
| Wygant, L | 1 |
| Nery, F | 1 |
| Reese, H | 1 |
| Pollack, MH | 2 |
| Mazza, M | 1 |
| Martini, A | 1 |
| Scoppetta, M | 1 |
| Mazza, S | 1 |
| Jensen, JE | 1 |
| Simon, NM | 1 |
| Kaufman, RE | 1 |
| Renshaw, PF | 1 |
1 review available for piracetam and Anxiety Disorders
| Article | Year |
|---|---|
A systematic review of the behavioral effects of levetiracetam in adults with epilepsy, cognitive disorders, or an anxiety disorder during clinical trials.
Topics: Anticonvulsants; Anxiety Disorders; Cognition Disorders; Cross-Over Studies; Double-Blind Method; Dr | 2003 |
3 trials available for piracetam and Anxiety Disorders
| Article | Year |
|---|---|
Levetiracetam for the treatment of co-occurring alcohol dependence and anxiety: case series and review.
Topics: Adult; Alcohol Drinking; Alcoholism; Anxiety Disorders; Diagnosis, Dual (Psychiatry); Female; Humans | 2008 |
Effect of levetiracetam on depression and anxiety in adult epileptic patients.
Topics: Adult; Age Factors; Anticonvulsants; Anxiety Disorders; Depressive Disorder; Dizziness; Epilepsies, | 2008 |
High-field MRS study of GABA, glutamate and glutamine in social anxiety disorder: response to treatment with levetiracetam.
Topics: Adolescent; Adult; Aged; Anxiety Disorders; Female; gamma-Aminobutyric Acid; Glutamic Acid; Glutamin | 2008 |
3 other studies available for piracetam and Anxiety Disorders
| Article | Year |
|---|---|
Effect of sleep patterns on levetiracetam induced mood changes.
Topics: Adult; Analysis of Variance; Anticonvulsants; Anxiety Disorders; Circadian Rhythm; Depressive Disord | 2017 |
Tolerability of levetiracetam in elderly patients with CNS disorders.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aging; Anticonvulsants; Anxiety Disorders; Central Nervo | 2003 |
Levetiracetam as adjunctive therapy for refractory anxiety disorders.
Topics: Adult; Aged; Anticonvulsants; Anxiety Disorders; Female; Humans; Levetiracetam; Male; Middle Aged; P | 2007 |